
































































































































































In	 the	past	decades,	 the	 scientific	 community	has	made	progress	 in	 studying	not	only	 the	
physical	object	"human"	in	terms	of	its	innate	complexity	and	nature,	but	also	the	close	and	
fundamental	symbiosis	with	complex,	dynamic	communities	of	other	organisms.	




of	 commensal,	 symbiotic	 and	 pathogenic	 microorganisms,	 such	 as	 bacteria,	 fungi	 (mainly	
yeasts),	 protozoa,	 archaea,	 and	 viruses	 (mainly	 bacteriophages)	 (Ferranti	 et	 al.	2014).	 The	
whole	system	is	entitled	“microbiota”.		The	microbiota	is	located	at	different	sites	of	human	
body,	mainly	the	ones	exposed	to	the	outer	world,	(e.g.	gastrointestinal	tract,	skin,	oral	and	
nasal	 cavity,	 vagina	 and	 urogenital	 apparatus,	with	more	 than	 70%	 of	 all	microbes	 in	 the	













range	 interactions	which	 lead	 to	 changes	 in	 the	overall	 system.	The	 inability	 to	 study	as	a	
whole	system,	leaves	us	with	one	preferential	option:	studying	the	local	changes	and	short-
range	interactions	in	order	to	establish	the	general	rules	that	govern	the	whole	system,	always	







is	 potentially	 expressing	 around	 4	million	 distinct	 genes.	Most	 of	 these	 genes	 encode	 for	
proteins	(i.e.	enzymes)	involved	in	the	digestion	of	food	and	metabolic	reactions	essential	for	
host	homeostasis.	This	 complex	 system	could	be	compared	 to	a	bioreactor	 that	generates	
molecules	 interacting,	 both	 directly	 and	 indirectly,	 with	 immune-system,	 epigenome	 and	







IME	 influences	human	processes	 that	determines	also	our	behaviour	and	the	 fundamental	







There	 is	 an	 extraordinary	 interpersonal	microbiota	 variability	within	 the	 human	 gut.	 Each	
individual	has	a	unique	microbiota	composed	of	distinct	combination	of	microorganisms.	This	










another	 proof	 of	 the	 microbiota	 originality	 (Tojo	 et	 al. 2014). Despite	 the	 considerable	
variability	 in	 the	 composition	 of	 the	 gut	 microbiota	 between	 individuals,	 the	 core	 set	 of	
redundant	 genes,	 among	 different	 bacterial	 species,	 remains	 stable	 over	 years.	 This	




responses	 to	 the	 external	 stimuli	 like	 therapeutic	 treatment,	 diet	 and	 lifestyle.	 Intestinal	






on	 the	 efficacy	 of	 therapeutic	 treatments	 (Iida	 et	 al.	 2013).	 The	 dietary	 habits	 have	 the	






in	 microbiota	 composition	 (Suez	 et	 al. 2014).	 Specifically,	 the	 metabolic	 functions	 of	 the	
intestinal	 microbiota	 of	 a	 single	 subject	 regulate	 food	 processing	 and	 therefore	 nutrient	
availability.	Significant	changes	in	microbiota	composition	affect	the	reactions	that	transform	
ingested	 food	 into	 nutrients	 available	 for	 the	 absorption.	 Based	 on	 these	 observations,	
nutritional	science	should	take	into	account	also	the	connection	between	dietary	intervention	
and	microbiota.	This	correlation	has	been	confirmed	by	several	cases.	For	instance,	the	study	
performed	 by	 Hazen	 and	 colleagues	 (Koeth et	 al. 2013)	 demonstrated	 a	 cause-effect	 link	































fermentation.	 Enterotype	 II	 is	 enriched	 in	Prevotella	 and	Desulfovibrio,	which	 are	 bacteria	
specialized	in	the	degradation	of	complex	dietary	fibers.	Enterotype	III	is	rich	in	Ruminococcus	







observed	 in	non-Russian	metagenomes	 (Tyakht	et	al.	 2013).	 This	notion	challenges	 current	
microbiota	subdivision,	suggesting	probably	the	existence	of	other	enterotypes.	Nonetheless,	















childbirth	 (natural	 or	 caesarean).	 It	 has	 been	 proposed	 that	 the	 new-born	 microbiota	
resembles	 the	 mother’s	 vaginal	 or	 skin	 microbiota	 depending	 on	 the	 first	 bacteria	
communities	that	the	new-born	encounters	during	the	delivery	(Dominguez-Bello	et	al.	2010).	
Therefore,	there	exists	a	similarity	between	mother’s	and	newborn’s	microbiota	promoted	by	
the	 vertical	 transmission	 of	 bacteria	 (faecal-oral,	 oral–oral	 and	 skin-oral	 routes)	 from	 the	
mother	to	the	newborn	(Adlerberth	and	Wold	2009).	The	study	by	Palmer	and	collaborators	
showed	that	the	earliest	gut	colonisers	are	generally	facultative	anaerobes,	followed	by	strict	







the	principal	source	of	energy	for	the	 intestinal	microbes	(Conlon	and Bird 2014).	 	The	gut	






















the	 primary	 into	 secondary	 bile	 acids	 such	 as	 deoxycholic	 acid,	 which	 exerts	 hepatotoxic	
effects	(Yoshimoto	et	al.	2013).	It	is	also	known	that	the	excess	of	lipids	in	the	diet	increases	
intestinal	permeability,	 leading	to	enhanced	translocation	of	bacterial	 lipopolysaccharide	in	
the	 bloodstream	 (Conlon	 and Bird 2014,	 Moreira	 et	 al. 2012).	 Further	 investigations	 are	






chain	 SCFAs	 (e.g.,	 isobutyrate	 and	 isovalerate)	 are	 formed	 during	 the	 fermentation	 of	
branched	chain	amino	acids	(Wong	et	al. 2006).	
In	 the	caecum	and	colon	 the	 fermentation	 is	very	 intense,	 leading	 to	a	high	production	of	
SCFAs,	 pH	 reduction	 (range	 5-6)	 and	 rapid	 bacterial	 growth.	 In	 the	 distal	 colon	 the	
fermentation	process	almost	stops	due	to	the	lack	of	substrates,	leading	to	a	higher	pH	and	
putrefactive	processes.	
The	 SCFAs	 have	 many	 important	 functions	 in	 the	 host	 physiology.	 i)	 Butyric	 acid	 for	
consistency	 serves	 as	 the	 principal	 source	 of	 energy	 for	 colonocyte	 differentiation	 and	
apoptosis,	 and	 therefore	 it	 is	 essential	 for	 maintaining	 mucosal	 integrity	 and	 protection	
against	 colon	 cancer	 (Brinkworth	 et	 al. 2009).	 Furthermore,	 butyrate	modulates	 intestinal	
inflammation	responses	and	regulates	glucose	metabolism	through	the	hormone	glucagon-





considered	 an	 additional	 source	 of	 energy	 for	 the	 host	 (used	mainly	 for	 the	 synthesis	 of	







Africa	 and	 South	 America,	 are	 plausibly	 due	 to	 the	 industrialization	 processes	 in	 food	
manufacturing,	 as	 all	 foodstuff	 nowadays	 is	 processed	 in	 order	 to	 increase	 shelf-life,	
decreasing	at	the	same	time	the	presence	of	microorganisms.	In	comparison,	the	diet	of	our	
forefather	consisted	of	 fermented	foods	 (fermentation	was	a	widespread	method	for	 food	
conservation),	that	was	also	a	way	to	introduce	considerable	quantities	of	different	bacteria,	
increasing	 the	 overall	 microbial	 diversity	 in	 the	 intestine.	 Of	 note,	 nowadays	 the	 overall	
microbiome	richness	is	also	low	in	people	living	in	the	urban	areas	of	the	Western	world,	as	a	
possible	consequence	of	a	general	distancing	from	natural	environments	with	a	consequential	
little	 exposure	 to	 soil,	 animals,	 and	 associated	 microbes	 (Ferranti	 et	 al.	 2014).	 These	
environmental	and	lifestyle	changes	in	the	Western	world	have	created	a	need	to	reintegrate	
live	 bacteria	 that	 are	no	 longer	 introduced	with	 the	diet.	 In	 this	 context,	 strong	 industrial	
interests	arose	to	implement	the	knowledge	on	and	production	of	probiotics.	
The	term	probiotic,	meaning	“for	life,”	is	derived	from	the	Latin	word	(pro,	“in	favour	of”)	and	
the	 Greek	 word	 (bios,	 “life”).	 The	 word	 “probiotic”	 was	 first	 used	 in	 1965	 to	 describe	
“substances	 secreted	 by	 one	 microorganism	 which	 stimulates	 the	 growth	 of	 another”	 in	
antithesis	 with	 the	 term	 antibiotic	 (Lilly	 and	 Stillwell	 1965).	 Almost	 10	 years	 later,	 Parker	
(Parker	1974)	proposed	a	different	definition	of	probiotic	(“organisms	and	substances	which	
contribute	 to	 intestinal	 microbial	 balance”)	 which	 is	 not	 far	 from	 the	 currently	 accepted	






Probiotic	 microorganisms	 have	 been	 demonstrated	 to	 possess	 several	 health	 promoting	





of	 tight-junctions,	 reducing	 the	 epithelial	 permeability	 and	 possible	 translocation	 of	
pathogenic	agents	and	their	products.	(Patel	RM	and	Lin	2010).	In	addition,	several	probiotic	




host	 microorganisms	 conferring	 a	 health	 benefit.”	 (Gibson	 et	 al.	 2017).	 The	 concept	 of	
prebiotics	 has	 attracted	 increasing	 attention,	 stimulating	 both	 scientific	 and	 industrial	
interest.	However,	several	food	components,	especially	oligosaccharides	and	polysaccharides,	
















sequencing	 analysis	 enables	 characterization	 of	 microbial	 communities	 in	 different	




system	 and	 due	 to	 the	 technology	 used.	 These	 aspects	 of	 the	 data	 analysis	 in	microbiota	
research	are	discussed	in	the	next	paragraphs.	
1.2.1	Next	generation	sequencing	technologies	
NGS	 technologies	 come	 from	 the	 Sanger	method	 based	 on	 the	 selective	 incorporation	 of	
chain-terminating	 dideoxynucleotides	 in	 the	 first	 automatic	 sequencing	 machine	 was	
produced	 by	 Applied	 Biosystems	 in	 1987;	 (Liu	 et	 al. 2012).	 Currently,	 there	 are	 several	













that	 includes	 both	 very	 conserved	 and	 variable	 sequences.	 Conventionally,	 only	 specific	





whole	 gene	 (about	 1.5	 kb),	 sequencing	 the	 full	 gene	 would	 lead	 to	 decreased	 depth	 of	
sequence	coverage,	making	it	more	difficult	to	detect	the	rare	taxa	present	in	the	sample.	
Specifically,	 the	 16S	 rRNA	 gene	 contains	 nine	 hypervariable	 regions	 (Vn),	which	 possess	 a	
sequence	divergence	that	permit	the	potential	discrimination	of	bacterial	taxa	to	the	level	of	
species.	Not	all	the	Vn	have	different	sequences	among	different	species.	In	fact,	some	species	
can	 be	 distinguished	 only	 by	 one	 of	 the	 nine	 Vn.	 Schloss	 (2010)	 reported	 that	 the	 use	 of	
different	variable	regions	influences	the	richness	and	evenness	of	communities	(Schloss	2010).	
Since	the	usage	of	any	specific	Vn	of	the	16S	rRNA	gene	has	advantages	and	disadvantages,	


























step.	 Sequencing	 errors	 can	 lead	 to	minor	 different	 amplicon	 sequences	 within	 a	 species	
creating	an	overestimation	of	bacterial	diversity.	To	limit	this	bias,	the	reads	are	aligned	based	
on	their	similarity	and	grouped	in	clusters.	Typically,	97%	similarity	is	used	as	a	cut-off	for	the	
approximate	 clustering	 with	 species-level	 resolution,	 that	 corresponds	 to	 the	 operational	
taxonomic	units	(OTUs)	(Goebel	and	Stackebandt	1994).	Based	on	the	number	of	clustered	
sequences	present	 in	the	sample,	 it	 is	possible	to	extrapolate	the	richness	of	the	biological	
sample,	even	if	the	clusters	are	not	associated	to	a	taxonomy	at	this	point.	This	phase	is	called	








though	 reference	 picking	 is	 quicker	 and	 creates	 less	 errors,	 this	 approach	 has	 the	
disadvantages	 of	 discarding	 many	 potentially	 valid	 sequences	 due	 to	 factors	 such	 as	
mismatches	in	the	database.		
The	annotation	of	the	OTUs	is	the	last	step	in	the	bioinformatics	pipeline.	For	this	step,	one	
sequence	 is	 selected	 per	 each	 cluster	 and	 compared	 with	 the	 sequences	 in	 a	 16S	 rRNA	
database	in	order	to	assign	the	taxonomy	to	each	specific	OTU	cluster.			
1.2.4	Biodiversity	determination	






















The	 output	 of	 the	 beta	 diversity	 analysis	 is	 a	 square	matrix	 that	 determines	 the	 distance	
between	samples.	This	matrix	is	called	distance	matrix.	The	UniFrac	distance	analysis,	which	






























on	the	sequencing	chip.	The	area	available	 for	sequence	 immobilization	 is	 limited	allowing	
only	 for	a	 small	 fraction	of	 the	 fragments	present	 in	 the	 sample	 to	actually	be	bound	and	




























if	 the	 difference	 in	 expression	of	 different	OTUs	 is	 significant.	 To	 control	 the	 rate	 of	 false	
positive	genes,	it	is	necessary	to	recognize	the	factor	Q	>	0	and	to	estimate	its	value.	Many	
false	 positive	 OTUs	 appear	 significantly	 differentially	 expressed	 between	 experimental	
conditions	under	the	assumption	of	a	Poisson	distribution	(Q	=	0)	but,	nevertheless,	they	are	
not	significant	in	tests	that	account	for	the	larger	variance	as	in	the	16S	rRNA	sequencing.	With	




The	analyses	described	above	allow	only	 for	 identification	of	OTUs	differentially	 abundant	
between	 different	 groups	 of	 samples	 (representing	 different	 conditions),	 but	 they	 do	 not	
provide	any	information	about	the	causing	factors	leading	to	this	differential	abundance.	In	
order	 to	 speculate	on	 the	potential	 causes	at	 the	origin	of	observed	microbiota	variations	
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The	 aim	 of	 this	 PhD	 work	 was	 the	 characterization	 of	 the	 intestinal	 microbial	 ecosystem	
through	bioinformatic	and	statistical	analyses	of	the	microbiomics	data	originated	from	three	













• Irritable	 bowel	 syndrome	 (IBS)	 observational	 study:	 The	 aim	 of	 this	 trial	 was	 the	
characterization	of	the	IME	in	human	subjects	affected	by	IBS.	The	characterization	was	
















Barbaro	MR,	Bellacosa	 L,	 Stanghellini	 V	 and	Barbara	G	 (2017).	 Effect	 of	 Lactobacillus	














The	 prevailing	 notion	 that	 the	 deliberate	 intake	 of	 viable	 cells	 of	 certain	 microorganisms	
through	 food	 and	 supplements	 may	 be	 beneficial	 for	 health	 underlies	 the	 worldwide	






demonstrated	 the	 efficacy	 of	 different	 probiotic	 preparations	 in	 a	 number	 of	 pathological	












detrimental	 microorganisms	 (Goulet	 O.	 2015).	 Therefore,	 modification	 of	 the	 intestinal	













profiling	 together	with	 short-chain	 fatty	 acid	 (SCFA)	 quantification	 in	 faecal	 samples	 from	









years)	 participated	 in	 the	 study,	 named	 PROBIOTA-Bb:	 “Effect	 of	 the	 probiotic	 strain	
Bifidobacterium	bifidum	Bb	on	the	faecal	microbiota	of	healthy	adults.”	All	patients	provided	
written	informed	consent,	and	the	study	protocol	was	approved	by	the	Ethics	Committee	for	










the	 2	months	 before	 the	 first	 visit,	 presence	 of	 gastrointestinal	 disorders	 (e.g.,	 diarrhoea,	
inflammatory	bowel	disease,	or	irritable	bowel	syndrome),	pregnancy	or	breastfeeding,	and	
recent	or	presumed	episodes	of	alcoholism	or	drug	addiction.	Participants	in	the	study	were	



























respectively)	 (Figure	 1).	 During	 each	 consultation,	 participants	 completed	 a	 short	 food	


















contained	 3.8	 ×	 109	 bacterial	 cells	 per	 capsule.	 The	 capsules	 also	 contained	maltodextrin,	










delivery,	 stool	 specimens	 were	 immediately	 stored	 at	 −80°C	 until	 metagenomic	 DNA	
extraction,	which	was	performed	within	14	days	by	means	of	a	QIAamp	DNA	stool	minikit	
(Qiagen,	 Valencia,	 CA),	 according	 to	 the	 manufacturer's	 specifications,	 adopting	 a	
temperature	of	95°C	in	step	three	to	maximize	bacterial	cell	lysis.	
3.1.2.5	Profiling	of	faecal	microbiota	composition	
The	 bacterial	 community	 structure	 of	 faecal	 samples	 was	 determined	 by	 16S	 rRNA	 gene	
profiling,	 as	 previously	 described	 (Milani	 C.	 et	 al.	 2013).	 In	 brief,	 a	 DNA	 fragment	
encompassing	the	variable	region	V3	of	the	16S	rRNA	gene	was	amplified	from	metagenomic	
DNA	 with	 the	 primers	 Probio_Uni	 (5ʹ-CCTACGGGRSGCAGCAG-3ʹ)	 and	 Probio_Rev	 (5ʹ-
ATTACCGCGGCTGCT-3ʹ)	 and	 was	 sequenced	 by	 means	 of	 Ion	 Torrent	 PGM	 sequencing	
technology	(Life	Technologies,	Carlsbad,	CA).	Specifically,	emulsion	PCR	was	performed	using	
the	Ion	OneTouch	200	template	kit	version	2	DL	(Life	Technologies,	Guilford,	CT),	according	to	













intervention	 trial.	 The	 remaining	 two	 subjects	 were	 excluded	 from	 the	 analysis	 due	 to	







(UPLC-HR-MS)	 analysis,	 samples	were	 diluted	 1:100	 in	 0.001%	HCOOH	 and	 centrifuged	 at	
3,000	×	g	for	1	min.	
UPLC-HR-MS	analysis	was	carried	out	on	an	Acquity	UPLC	separation	module	(Waters,	Milford,	





eluents	 were	 0.001%	 HCOOH	 in	 MilliQ-treated	 water	 (solvent	 A)	 and	 CH3OH:CH3CN	 (1:1	
[vol/vol],	 solvent	 B).	 A	 5-μl	 aliquot	 of	 the	 sample	 was	 separated	 by	 the	 UPLC	 using	 the	
following	elution	gradient:	0%	B	for	4	min,	0	to	15%	B	in	6	min,	15	to	20%	B	in	5	min,	20%	for	
13	 min,	 and	 then	 return	 to	 initial	 conditions	 in	 1	 min.	 The	 column	 and	 samples	 were	
maintained	at	30	and	15°C,	respectively.	The	UPLC	eluate	was	analyzed	in	full-scan	MS	in	the	
range	m/z	50	to	130.	The	resolution	was	set	at	50	K,	the	automatic	gain	control	(AGC)	target	





corresponding	 to	 the	 formic	 acid	 dimer	 [2M-H]−,	 was	 used	 as	 the	 lock	 mass.	 The	 mass	
tolerance	 was	 2	 ppm.	 The	 MS	 data	 were	 processed	 using	 Xcalibur	 software	 (Thermo	
Scientific).	Analytical-grade	SCFAs	were	used	as	standards	(Sigma-Aldrich,	Milan,	Italy).	Five-
point	 external	 calibration	 curves	were	 adopted	 to	 quantify	 pyruvic,	 lactic,	 succinic,	 acetic,	













compared	 before	 versus	 after	 placebo.	 This	 analysis	 allowed	 us	 to	 decide	 whether	 the	









Shannon	 divergence	 (JSD)	 distance	 and	 the	 Partitioning	Around	Medoids	 (PAM)	 algorithm	














related	 to	 slight	 seasonal	 differences	 in	 the	 availability	of	 fruits	 and	 vegetables	 (the	 study	
began	 in	 June	 and	 ended	 in	 October).	 Participants'	 adherence	 to	 the	 study	 protocol	 was	
assessed	based	on	capsule	counts	and	faecal	sample	collection,	and	compliance	was	higher	
than	 95%.	 In	 total,	 38	 participants	 were	 assessed	 for	 eligibility,	 and	 35	 participants	 were	
randomly	assigned;	27	participants	 (77%)	 concluded	 the	 study,	with	14	participants	 in	 the	
randomization	group	A	(6	females	and	8	males)	and	13	participants	in	group	B	(7	women	and	
6	men).	 The	 drop-out	 rate	 of	 volunteers	who	 began	 the	 first	 treatment	was	 20%	 (n	 =	 7),	






















S2	 in	 the	 supplemental	 material)	 resembling	 the	 Bacteroides-dominant	 (Ba)	 and	 the	
Prevotella-dominant	 (Pr)	 enterotypes	 (Arumugam	 et	 al.	 2011).	 During	 the	 study,	 8	 of	 27	
subjects	changed	enterotypes;	specifically,	we	observed	11	shifts	from	one	enterotype	to	the	
other	(accounting	for	the	14.7%	of	all	possible	shifts),	with	3	during	the	probiotic	intervention,	
5	 in	 the	 placebo	 treatment,	 and	 3	 in	 the	 washout	 phase	 (Figure	 S2B).	 Therefore,	 the	











(OTUs)	 in	 each	 sample	 (α-diversity)	 and	 the	 intersample	 relationship	 of	 the	 bacterial	













(from	 phylum	 to	 genus)	 that	 were	 significantly	 affected	 by	 the	 probiotic	 or	 placebo	
treatments.	This	nonparametric	statistical	analysis	revealed	that	B.	bifidum	Bb	intake	had	a	
greater	 impact	 than	 placebo	 on	 the	 relative	 abundance	 of	 OTUs	 (see	 Table	 S1	 in	 the	










Figure	 2.	Relative	 abundance	of	 dominant	 bacterial	 families	 in	 faecal	 samples	 significantly	
modified	 by	 the	 probiotic	 treatment.	 Data	 are	 shown	 as	 Tukey	 box	 plots.	 Statistically	














reads	 associated	 with	 the	 B.	 bifidum	 species	 increased	 importantly	 upon	 probiotic	
consumption,	changing	from	a	median	below	the	detection	limit	to	0.005%.	In	contrast,	during	







the	 supplemental	material).	 Statistical	 analyses	 (repeated-measures	 ANOVA	 and	Wilcoxon	
test)	 revealed	that	neither	the	probiotic	nor	placebo	 intervention	significantly	affected	the	
levels	of	SCFAs	quantified	in	all	faecal	samples	(see	Table	S4	in	the	supplemental	material).	
Subsequently,	 we	 clustered	 subjects	 by	 PCoA	 based	 on	 the	 concentrations	 of	 the	 most	
abundant	 faecal	 SCFAs,	 i.e.,	 acetate,	 butyrate,	 and	 propionate.	 According	 to	 the	 highest	
Silhouette	coefficient	of	clustering	prediction	 (SI	=	0.43),	we	separated	the	samples	 in	 two	
groups	 (Figure	 3A),	 which	 do	 not	 correspond	 to	 enterotype	 clusters.	 SCFA	 group	 H	 was	
characterized	 by	 higher	 concentrations	 of	 acetate,	 butyrate,	 isovalerate,	 propionate,	
succinate,	and	valerate	than	the	second	group	(SCFA	group	L;	Figure	3B).	Furthermore,	SCFA	









































the	 first	 two	 principal	 components	 are	 shown);	 clustering	 was	 based	 on	 the	 faecal	
concentrations	of	acetate,	butyrate,	and	propionate	using	JSD	distance	and	the	Partitioning	
around	Medoids	(PAM)	algorithm.	(B)	Tukey	box	plots	representing	the	proportion	of	main	
faecal	 SCFAs	 in	 groups	 H	 (displaying	 higher	 concentrations	 of	 SCFAs)	 and	 L	 (lower	 SCFA	
concentrations).	 (C)	 Tukey	box	plots	of	 the	 ratios	between	 the	 three	main	 faecal	 SCFAs	 in	
groups	H	 and	 L.	 (D)	 Tukey	 box	 plots	 representing	 the	 effect	 of	 the	 probiotic	 and	 placebo	
intervention	 on	 butyrate	 levels	 in	 SCFA	 groups	 H	 and	 L.	 Asterisks	 are	 according	 to	 the	
Wilcoxon-Mann-Whitney	 test	 (with	 paired	 data,	 when	 possible)	 with	 Benjamini-Hochberg	








The	 PROBIOTA-Bb	 trial	 was	 undertaken	 to	 contribute	 to	 the	 elucidation	 of	 the	 probiotic	
potential	 of	 strain	 of	 the	 species	 Bifidobacterium	 bifidum,	 which	 is	 a	 specialized	 human	
commensal	 possessing	 a	 large	 arsenal	 of	 host	 interaction	 properties	 (Turroni	 et	 al.	 2014).	
Specifically,	we	 studied	 the	 impact	 of	B.	 bifidum	 Bb	on	 the	 intestinal	microbial	 ecology	of	
healthy	 adults.	 Strain	 Bb	 was	 isolated	 from	 the	 feces	 from	 a	 healthy	 adult	 woman	 and,	
according	to	in	silico	analysis	of	its	draft	genome	(our	unpublished	data),	possesses	the	genetic	





the	 minimal	 daily	 dosage	 recommended	 for	 probiotics	 by	 the	 Italian	 Ministry	 of	 Health	
(Ministero	della	Salute	2013).	
16S	rRNA	gene	profiling	revealed	considerable	variation	of	the	faecal	microbiota	composition	




To	 characterize	 the	 wide	 interindividual	 variability	 of	 the	 faecal	 microbiota,	 we	 clustered	
samples	according	to	common	features	in	the	taxonomic	composition.	In	light	of	the	theory	
suggesting	 that	 intestinal	 microbiota	 variation	 is	 generally	 stratified	 and	 not	 continuous	
(Arumugam	et	al.	2011),	we	adopted	the	enterotype	classification	to	cluster	the	data	collected	
during	the	PROBIOTA-Bb	study,	according	to	the	relative	abundance	of	bacterial	genera.	The	
proposed	 approach	 for	 enterotyping	 is	 subject	 to	 limitations.	 In	 particular,	 enterotyping	








appropriate	 prediction	 model.	 Nonetheless,	 we	 used	 the	 original	 tutorial	 to	 define	
enterotypes	(http://enterotype.embl.de/enterotypes.html)	in	the	present	study,	because	it	
has	been	demonstrated	to	be	useful	to	correlate	the	gut	microbial	community	structure	with	
host	 biomarkers	 and	 diet	 (Wang	 et	 al.	 2014,	 Vandeputte	 et	 al.	 2016).	 In	 our	 study,	








of	 this	 study,	 induced	 a	 significant	 change	 in	 the	β-diversity	 in	 terms	of	weighted	UniFrac	
distances.	 Kim	 et	 al.	 (Kim	 et	 al.	 2013)	 did	 not	 observe	 significant	 alterations	 in	 α-	 and	 β-
diversities	following	the	consumption	of	various	probiotic	products;	however,	a	very	limited	
number	 of	 subjects	 per	 group	 (only	 three)	 were	 used	 in	 that	 study.	 Furthermore,	 no	
alterations	in	α-	and	β-diversities	were	observed	in	the	faecal	microbiota	of	1-	to	2-year-old	
children	following	the	consumption	of	probiotic	milk	containing	Lactobacillus	rhamnosus	GG	














and	 Rikenellaceae	 increased,	 whereas	 Prevotellaceae	 decreased.	 Remarkably,	
Ruminococcaceae,	 Prevotellaceae,	 and	 Rikenellaceae	 (together	 with	 Lachnospiraceae	 and	
Bacteroidaceae)	have	been	identified	by	metatranscriptomics	as	the	predominant	families	of	
the	active	microbiota	(Gosalbes	et	al.	2011).	
Ruminococcaceae	 is	 a	 family	 of	 obligate	 anaerobes	 that	 include	 bacteria	 (e.g.,	
Faecalibacterium,	Ruminiclostridium,	 and	Ruminococcus	 spp.)	 that	may	degrade	numerous	
polysaccharides	in	the	lower	gastrointestinal	tract,	such	as	starch,	cellulose,	and	xylan,	and	
produce	SCFAs	(Flint	et	al.	2008).	The	expansion	of	Ruminococcaceae	in	centenarians	has	been	
reported,	 with	 a	 positive	 correlation	 with	 high-fiber	 diets	 (Wang	 et	 al.	 2015)	 and	 after	
intervention	with	resistant	starch	(Salonen	et	al.	2014).	Furthermore,	in	the	study	by	Martínez	






















abundance	 of	Prevotellaceae	 in	 the	 terminal	 ileum	microbiota	 of	 subjects	with	 ankylosing	
spondylitis	(AS)	compared	with	healthy	controls	(Costello	et	al.	2015).	




microorganisms	 represent	active	and	 rapidly	 reacting	 components	of	 the	human	 intestinal	
microbiota	 (Gosalbes	 et	 al.	 2011).	Notably,	Prevotella	 spp.	 are	 the	dominant	 colonizers	 of	









phylum)	 is	 inversely	 associated	with	 the	 relative	 richness	 of	Ruminococcaceae	 (Firmicutes	
phylum).	For	 instance,	 increased	Ruminococcaceae	have	been	proposed	to	compensate	for	
lower	 levels	 of	 Prevotellaceae	 in	 Parkinson's	 disease	 patients	 (Scheperjans	 et	 al.	 2015).	
Conversely	to	Ruminococcaceae,	Prevotellaceae	have	been	observed	to	be	overrepresented	
in	obese	people	 (Zhang	et	al.	2009).	 Furthermore,	although	 typically	associated	with	plant	
carbohydrate	consumption,	enriched	abundance	of	Prevotella	has	also	been	linked	to	the	high	
consumption	of	L-carnitine-containing	foods,	such	as	red	meat	(Koeth	et	al.	2014).	
Notably,	 several	 studies	 also	 suggested	 a	 potential	 role	 of	 Prevotellaceae	 as	 intestinal	
pathobionts.	 The	 family	 Prevotellaceae	 was,	 in	 fact,	 demonstrated	 to	 elicit	 a	 strong	
inflammatory	 response	 in	 the	 guts	 of	mice	 (Elinav	 et	 al.	 2011)	 and	 is	 overrepresented	 in	






and	 in	 children	diagnosed	with	 irritable	bowel	 syndrome	 (Rigsbee	et	al.	2012).	 Finally,	 the	
species	 Prevotella	 copri	 was	 identified	 as	 strongly	 correlated	 with	 disease	 in	 new-onset	
untreated	rheumatoid	arthritis	patients	(Scher	et	al.	2013).	However,	increased	abundance	of	
P.	 copri	 has	 also	 been	 associated	 with	 dietary	 fiber-induced	 improvement	 in	 glucose	 and	
insulin	 responses	 (Kovatcheva-Datchary	 et	 al.	 2015).	 In	 addition,	 low	Prevotellaceae	 levels	
have	been	reported	 in	patients	with	type	1	diabetes	(Brown	et	al.	2011)	and	children	with	
autism	 (Kang	 et	 al.	 2013).	 However,	 a	 subsequent	 study	 involving	 a	 larger	 population	 of	
autistic	children	reported	the	opposite	result	(i.e.,	a	significant	increase	in	Prevotella	spp.	[Son	




Prevotella	 spp.,	which	appear	 to	be	critical	bacteria	 for	healthy	microbiota	 that	have	been	
linked	 to	 plant-rich	 diets	 but	 also	 to	 chronic	 inflammatory	 conditions	 (Ley	 et	 al.	 2016).	 In	
addition,	 genera	 such	 as	 Prevotella	 include	 numerous	 species	 that	 possess	 wide	 genetic	





SCFAs	 in	 the	 intestinal	 lumen	 by	 affecting	 their	 uptake/utilization	 by	 host	 and	 intestinal	
microbes	or	by	changing	the	relative	abundance	of	specific	butyrate-producing	bacteria.	 In	
our	 study,	 we	 observed	 the	 modification	 of	 Clostridiales	 bacteria	 of	 the	 family	



















butyrate	 concentrations	 or	 increase	 low	 butyrate	 concentrations	 to	 maintain	 butyrate	














(PCoA)	 based	on	Weighted	Unifrac	 expressing	 the	β-diversity	 of	 samples.	Axes	 of	 the	 two	
panels	are	the	two	most	informative	components	explaining	the	differences	among	samples	





treatment	 (|v|	 =	 √	 [(xi-xj)2+	 (yi-yj)2],	 where	 «i»	 indicates	 before	 treatment	 and	 «j»	 after	
treatment).	Paired	points	are	the	sample	before	and	the	sample	after	a	treatment	for	a	specific	







Figure	 S2.	 Analyses	 of	 enterotypes	 in	 samples	 of	 the	 PROBIOTA-Bb	 trial.	 A.	 Principal	
Coordinated	Analysis	 (PCA;	 the	 first	 two	 principal	 components	 are	 shown);	 clustering	was	
based	on	genus	relative	abundance	using	JSD	distance	and	the	Partitioning	Around	Medoids	
(PAM)	algorithm.	The	optimal	number	of	clusters	was	determined	through	Calinski-Harabasz	
(CH)	 index	 (59)	 and	 the	 Silhouette	 coefficient.	 B,	 shifts	 between	 enterotypes	 of	 faecal	
microbiota	compositions	in	a	single	subject;	red,	blue,	and	dotted-black	arrows	indicate	shifts	


















ALL SUBJECTS p values baseline    post 
PROBIOTIC    
k_Bacteria;Other 0.030 1.536% 2.812% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;g_ 0.018 0.162% 0.364% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae 0.041 14.179% 11.973% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella 0.034 14.158% 11.963% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae 0.010 3.987% 5.919% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_undefined 0.013 3.823% 5.640% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;Other 0.015 0.120% 0.158% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_Alistipes 0.013 0.044% 0.122% 
p_Firmicutes;c_Bacilli;o_Bacillales;f_Staphylococcaceae;g_Staphylococcus 0.023 0.000% 0.005% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_;g_undefined 0.044 0.000% 0.000% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_;Tissierellaceae;g_Peptoniphilus 0.029 0.001% 0.002% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae 0.005 0.405% 0.838% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_undefined 0.006 0.389% 0.810% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;Other 0.006 0.016% 0.027% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_Christensenella 0.042 0.000% 0.001% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Dehalobacteriaceae 0.042 0.002% 0.005% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Dehalobacteriaceae;g_Dehalobacterium 0.046 0.001% 0.004% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae 0.039 12.212% 15.271% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Anaerotruncus 0.029 0.026% 0.031% 
p_Firmicutes;c_Clostridia;o_Clostridiales;Other 0.008 1.289% 1.794% 
p_Firmicutes;c_Clostridia;Other 0.030 0.107% 0.215% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_;Eubacterium; 0.010 0.023% 0.056% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;Other 0.038 0.004% 0.017% 
p_Proteobacteria;c_Deltaproteobacteria;o_Desulfovibrionales;f_Desulfovibrionaceae 0.014 0.133% 0.245% 






PLACEBO    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;Other 0.036 1.095% 0.457% 
p_Firmicutes;c_Bacilli 0.012 0.030% 0.104% 
p_Firmicutes;c_Bacilli;o_Gemellales;f_Gemellaceae;g_undefined 0.038 0.000% 0.001% 
p_Firmicutes;c_Bacilli;o_Lactobacillales 0.030 0.027% 0.094% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Carnobacteriaceae;g_Granulicatella 0.008 0.000% 0.002% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Lactobacillaceae;g_Lactobacillus 0.019 0.001% 0.002% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Streptococcaceae;g_Streptococcus 0.019 0.022% 0.087% 
p_Firmicutes;c_Bacilli;o_Turicibacterales;f_Turicibacteraceae;g_Turicibacter 0.006 0.001% 0.008% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Peptococcaceae 0.025 0.001% 0.006% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_undefined 0.021 0.024% 0.010% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Veillonellaceae;g_Veillonella 0.017 0.018% 0.038% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_Holdemania 0.032 0.003% 0.015% 
p_Proteobacteria;c_Gammaproteobacteria;o_Pasteurellales;f_Pasteurellaceae;g_Haemophilus 0.012 0.002% 0.019% 
    
BEFORE TREATMENTS p values          V1  V3    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_S24;7;g_undefined 0.010 0.025% 0.033% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_Blautia 0.004 0.936% 0.413% 



















Bacteroides-dominated enterotype p values baseline    post 
PROBIOTIC    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;g_ 0.011 0.026% 0.072% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;Paraprevotellaceae;g_;Prevotella; 0.021 0.001% 0.367% 
p_Firmicutes;c_Clostridia;o_Clostridiales;Other;Other 0.039 1.169% 1.686% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;Other 0.005 0.012% 0.032% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_undefined 0.034 0.549% 0.655% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae;g_Christensenella 0.022 0.001% 0.001% 
p_Proteobacteria;c_Deltaproteobacteria;o_Desulfovibrionales;f_Desulfovibrionaceae;g_Bilophila 0.044 0.061% 0.146% 
PLACEBO    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;Other;Other 0.036 1.657% 0.457% 
p_Firmicutes;c_Bacilli;o_Gemellales;f_Gemellaceae;g_undefined 0.038 0.001% 0.001% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Carnobacteriaceae;g_Granulicatella 0.008 0.001% 0.002% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Lactobacillaceae;g_Lactobacillus 0.019 0.001% 0.002% 
p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Streptococcaceae;g_Streptococcus 0.019 0.025% 0.087% 
p_Firmicutes;c_Bacilli;o_Turicibacterales;f_Turicibacteraceae;g_Turicibacter 0.006 0.001% 0.008% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_undefined 0.021 0.032% 0.010% 
p_Firmicutes;c_Clostridia;o_Clostridiales;f_Veillonellaceae;g_Veillonella 0.017 0.017% 0.038% 
p_Firmicutes;c_Erysipelotrichi;o_Erysipelotrichales;f_Erysipelotrichaceae;g_Holdemania 0.032 0.003% 0.015% 








   post 
PROBIOTIC    
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;Other 0.024 0.051% 0.023% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella 0.014 34.416% 23.547% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;Other 0.002 0.057% 0.208% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_undefined 0.005 3.118% 6.478% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_Alistipes 0.024 0.063% 0.172% 
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;Barnesiellaceae;g_undefined 0.003 0.388% 1.092% 
PLACEBO    



























































- 0.14 20.48 0.77 5.37 2.19 1.25 1.59 1.51 
S03 0.40 0.78 39.45 1.72 9.91 5.16 - 2.77 2.73 
S04 0.26 0.47 18.12 1.71 14.82 8.51 - 2.29 2.62 
S05 - 0.47 160.15 19.39 39.77 57.22 32.31 0.59 2.49 
S07 0.44 0.95 47.04 1.73 14.18 2.41 - 3.19 3.25 
S08 0.25 0.55 6.59 1.97 2.72 3.22 - 1.51 1.85 
S13 0.25 0.35 21.65 1.47 16.16 - - 5.11 2.35 
S14 0.27 0.28 35.84 3.57 9.57 16.89 - 0.72 2.37 
S15 0.29 0.31 34.95 1.71 9.55 0.49 - 4.47 3.89 
S16 0.26 0.30 50.38 1.21 17.72 17.77 - 2.06 2.91 
S17 - 0.25 64.07 0.42 42.39 6.27 3.25 0.77 0.65 
S19 0.26 0.34 19.33 1.75 15.32 8.71 - 2.64 2.53 
S20 - 0.22 119.78 0.74 43.94 21.10 11.86 8.34 8.38 
S23 - 0.15 4.98 0.59 4.28 0.73 0.33 1.27 1.04 
S25 - 0.26 49.38 1.36 17.00 8.11 5.29 1.76 2.43 
S26 - 0.08 15.19 0.44 3.07 2.90 1.34 1.06 0.92 
S28 - 0.41 51.50 0.78 14.17 7.25 5.28 3.57 2.99 
S32 - 0.19 25.33 0.49 10.60 6.17 3.42 0.69 0.98 
S33 - 0.25 43.62 0.59 11.55 9.91 5.23 1.35 3.39 
S34 - 0.14 18.16 0.63 5.21 0.53 0.95 1.80 1.26 
S35 - 0.18 45.81 0.42 19.61 13.07 6.52 0.68 1.46 
S36 - 0.06 43.04 0.52 12.40 11.14 7.18 2.26 2.40 
S37 - 0.24 13.37 0.65 2.98 3.52 2.29 1.45 1.08 
S38 0.34 0.66 26.48 2.03 22.92 4.61 - 1.19 2.30 
S39 - 0.19 39.75 9.83 21.80 9.93 5.79 0.59 1.03 
S02 
After placebo 
- 0.14 12.89 0.72 2.37 - - 0.72 0.80 
S03 0.32 1.22 44.58 1.90 7.99 8.59 - 1.84 2.83 
S04 0.33 0.45 50.94 1.78 32.35 23.72 - 2.05 7.03 
S05 - 0.13 54.62 0.84 10.84 10.32 6.11 0.58 1.22 
S07 0.37 0.72 85.83 2.29 53.83 25.93 - 12.23 10.80 
S08 0.27 0.44 100.66 1.55 25.59 46.09 - 11.89 3.69 
S13 0.39 3.73 39.93 1.63 1.55 - - 1.00 1.98 
S14 0.23 0.25 26.11 2.74 13.60 12.94 - 1.37 3.02 
S15 0.26 0.43 13.30 1.34 7.44 3.08 - 2.29 3.13 





S17 - 0.23 40.35 0.44 34.27 9.05 4.77 0.21 1.27 
S19 0.28 0.26 48.10 1.66 30.41 22.20 - 3.00 6.60 
S20 - 0.22 96.93 0.81 39.93 20.78 13.14 2.40 5.98 
S23 - 0.51 10.79 0.64 7.33 1.89 1.47 1.55 1.10 
S25 - 0.31 40.49 0.60 11.36 5.75 3.92 2.30 2.64 
S26 - 0.84 34.78 0.76 7.99 4.99 2.96 1.95 1.56 
S28 - 0.11 34.66 0.40 10.20 7.77 4.13 0.19 1.26 
S32 - 0.15 19.44 1.28 6.87 4.49 2.30 0.68 0.83 
S33 - 0.16 24.86 0.59 4.17 1.10 0.44 0.93 1.72 
S34 - 0.10 10.02 0.57 4.28 1.49 1.92 3.31 2.15 
S35 - 0.53 63.90 0.60 33.36 17.38 8.52 1.13 2.50 
S36 - 0.12 40.79 0.66 9.57 9.41 6.61 3.30 2.22 
S37 - 0.27 15.25 0.48 2.69 2.71 1.39 1.06 0.92 
S38 0.32 1.01 66.25 1.81 43.33 10.98 - 2.45 3.83 
S3 - 0.14 61.15 1.44 36.84 18.10 10.55 1.93 3.07 

















































S02 Before Probiotic - 0.77 60.76 6.86 13.97 11.82 6.55 0.46 1.15 
S03 0.32 0.55 48.09 1.97 26.18 15.02 - 1.90 5.21 
S04 0.38 - 48.16 1.91 6.62 2.43 - 1.11 1.79 
S05 0.29 0.41 45.62 1.86 24.70 14.18 - 1.81 4.69 
S07 0.26 - 53.96 1.42 17.56 35.63 - 1.44 3.87 
S08 0.33 0.93 68.78 1.95 27.35 17.92 - 3.54 4.65 
S13 0.19 0.24 50.64 1.35 12.21 21.31 - 0.96 2.26 
S14 0.39 0.10 55.40 1.56 23.03 10.99 - 5.62 6.51 
S15 0.33 1.81 11.26 1.54 2.32 - - 1.55 2.00 
S16 0.25 0.74 34.82 1.29 13.21 7.53 - 5.21 4.18 
S17 - 0.23 23.95 0.85 9.09 3.71 2.60 2.19 2.62 
S19 0.27 0.22 19.41 1.62 9.52 5.82 - 1.78 2.64 
S20 - 0.23 33.17 0.86 18.85 8.09 4.46 1.06 1.63 
S23 - 0.28 103.38 0.72 38.66 18.21 11.16 2.37 6.07 
S25 - 0.44 2.77 0.39 1.00 0.67 - 0.43 0.60 
S26 - 0.56 53.49 1.25 25.25 22.22 13.35 2.05 2.66 
S28 - 0.19 40.23 0.39 16.29 6.60 3.70 0.42 0.97 
S32 - 0.95 38.44 0.55 11.18 9.18 4.93 0.96 2.29 
S33 - 0.18 17.55 0.45 6.14 1.61 1.86 2.74 1.46 
S34 - 0.15 44.40 0.90 9.68 4.51 2.73 1.67 1.56 





S36 - 0.16 37.61 0.59 11.39 6.16 3.28 1.38 2.41 
S37 - 0.30 93.50 0.84 37.23 20.43 12.63 3.02 4.40 
S38 - 0.14 48.60 0.44 15.82 17.06 11.29 4.34 3.25 
S39 - 0.17 37.38 0.70 9.41 2.45 2.31 2.75 2.00 
S02 After Probiotic - 0.16 51.95 0.87 11.69 11.98 7.54 0.82 1.38 
S03 0.37 0.46 72.93 1.46 33.96 20.33 - 10.18 6.95 
S04 0.38 1.02 22.04 1.61 8.78 2.03 - 2.40 2.10 
S05 0.30 0.27 64.70 13.36 29.99 17.95 - 8.98 5.71 
S07 0.22 - 45.78 1.83 15.27 27.40 - 1.77 2.70 
S08 0.36 1.51 47.32 2.32 6.77 3.99 - 2.48 2.72 
S13 0.27 0.25 8.31 1.44 6.37 3.76 - 2.46 2.57 
S14 0.35 1.92 76.83 1.70 26.52 9.40 - 5.26 5.71 
S15 0.36 1.96 42.40 1.56 7.59 1.32 - 3.91 2.53 
S16 0.22 0.36 41.66 1.56 14.03 19.97 - 3.18 3.34 
S17 - 0.22 10.39 0.46 2.40 0.65 - 0.65 0.84 
S19 0.34 0.29 33.83 1.82 13.34 9.99 - 2.93 3.08 
S20 - 0.24 110.13 1.07 49.00 15.48 9.41 2.68 4.23 
S23 - 0.74 32.00 2.46 10.27 8.17 4.31 0.43 1.06 
S25 - 0.16 40.94 0.52 12.79 11.48 7.77 3.92 3.47 
S26 - 0.42 41.81 1.17 17.25 18.09 10.81 3.77 2.73 
S28 - 0.28 52.20 0.41 35.10 13.17 7.41 0.49 2.09 
S32 - 0.26 12.12 0.94 7.84 4.28 2.76 1.96 1.67 
S33 - 0.32 18.60 0.53 3.58 1.66 1.11 1.63 1.06 
S34 - 0.23 30.22 0.75 7.91 6.47 4.05 2.14 1.55 
S35 - 0.19 63.94 0.42 16.85 21.64 11.98 1.03 4.10 
S36 - 0.17 42.63 0.74 20.16 10.47 5.92 1.71 2.15 
S37 - 0.09 77.39 0.98 30.90 15.21 9.51 2.59 3.94 
S38 - 0.08 43.43 0.49 - 11.00 8.21 4.32 2.54 











    All subjects  SCFA group L  SCFA group H 
 p values baseline post  p values baseline post  p values baseline post 
PROBIOTIC            
Acetate 0,833 101,44 106,58     0.268 30.97 40.65     0.365 62.02 51.13 
Butyrate 0,271 22,78 27,51  0.025 * 4.93 8.71  0.042 * 18.62 13.39 
Isovalerate 0,853 5,37 6,15  0.217 1.73 2.23  0.465 2.50 3.92 
Lactate 0,653 0,82 1,27  0.808 0.41 0.41  0.919 0.39 0.54 
Propionate 0,711 38,70 44,49  0.068 9.27 14.95  0.102 23.81 17.18 
Succinate 0,508 5,65 2,90  0.502 0.89 0.93  0.278 1.84 2.55 
Valerate 0,426 5,88 7,40  0.502 2.06 2.41  0.365 4.06 3.45 
            
PLACEBO            
Acetate 0,937 111,58 113,16  0.179 29.53 40.23  0.125 98.60 55.27 
Butyrate 0,916 27,38 26,92  0.083 5.97 10.89  0.375 25.59 11.61 
Isovalerate 0,120 5,1708 7,42  0.393 2.00 2.72  0.125 2.94 1.09 
Lactate 0,989 1,00 1,170  0.338 0.33 0.57  0.250 0.31 0.21 
Propionate 0,874 39,17 39,82  0.203 11.58 16.82  0.125 35.95 22.95 
Succinate 0,164 3,27 4,108  0.473 1.65 1.21  0.875 5.44 0.89 
Valerate 0,853 7,35 7,179  0.128 2.11 3.03  0.250 3.61 2.58 
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ecosystem	 of	 children	 and	 adolescents	 with	






pathways	 (primary)	 or	 secondary	 to	 underlying	 diseases.	 It	 may	 occur	 from	 pediatric	 age	 and	
represents	an	unquestioned	risk	factor	for	cardiovascular	diseases	(D'Adamo	et	al.	2015).		





the	 decrease	 of	 LDL-C	 and	 in	 the	 improvement	 of	 trygliceridaemia	 and	HDL-cholesterol	 (HDL-C)	














Although	 altered	 microbiota	 composition	 (generally	 called	 “dysbiosis”)	 has	 been	 associated	 to	
diseases	that	are	characterized	by	hyperlipidemia	such	as	obesity	(Kobyliak	et	al.	2016),	diabetes	
(Yamaguchi	et	al.	2016),	metabolic	diseases	(Woting	and	Blaut	2016)	and	non-alcoholic	fatty	liver	
disease	 (Wang	et	al.	 2016),	 the	 intestinal	microbial	ecosystem	 (IME)	has	never	been	 thoroughly	
investigated	in	young	people	with	inherited	hyperlipidemia.	
Hyperlipidemic	 subjects	 could	 benefit	 from	 dietary	 patterns/food	 products	 able	 to	 affect	 lipid	






























The	 recruited	hyperlipidemic	subjects	were	asked	 to	collect	a	 stool	 sample	before	and	after	 the	
intervention.	Thirty-four	 stool	 samples	were	collected	 for	analysis	at	baseline,	but	only	15	were	
available	after	the	eight	weeks	of	hazelnut	with	skin	consumption	(mean	and	median	age:	11;	min	
5,	max	17	years	old).	The	effect	of	the	dietary	intervention	on	the	faecal	microbiota	composition	
was	analyzed	 in	15	subjects,	whereas	 the	 levels	of	SCFAs	were	evaluated	 in	 the	whole	group	of	
children	and	adolescents	with	primary	hyperlipidemia	who	collected	stools	at	baseline.		
To	be	eligible,	screened	children	and	adolescents	were	required	to	be	normal-weight	with	diagnosis	











Subjects	 were	 excluded	 if	 they	 had	 food	 allergies	 or	 specific	 aversion	 for	 nut	 consumption,	
secondary	hyperlipidemias,	obesity	(body	mass	index,	BMI,	≥	90th	percentile,	age	and	sex	matched);	
renal,	endocrine,	liver	or	gastrointestinal	disorders	(e.g.,	diarrhoea,	inflammatory	bowel	disease,	or	








All	 patients	 enrolled	 were	 under	 nutritional	 recommendations	 suggested	 for	 pediatric	
hyperlipidemia	based	on	the	cardiovascular	health	integrated	lifestyle	diet	(CHILD-1)	(Expert	Panel	
on	Integrated	Guidelines	for	Cardiovascular	et	al.	2011).	Dietary	intervention	consisted	of	8-week	




30	 g,	 which	 is	 the	 recommended	 daily	 dose	 for	 an	 adult).	 All	 participants	 were	 encouraged	 to	
maintain	the	same	dietary	pattern	and	lifestyle	habits	throughout	the	8-week	intervention	study.	
Subjects	 had	 to	 exclude	 the	 intake	 of	 other	 nuts,	 dried	 fruits,	 probiotic	 or	 prebiotic	 foods	 or	
supplements	 from	 one	 month	 before	 the	 beginning	 of	 the	 study	 until	 the	 end	 of	 the	
experimentation.	 Traditional	 yogurt	 was	 allowed.	 To	 check	 the	 compliance	 to	 the	 dietary	
recommendations,	subjects	and	their	families	were	asked	to	fill	in	weekly	food	diaries.		
At	 baseline	 and	 at	 the	 end	 of	 the	 HZN+S	 intervention	 (0	 and	 8	 weeks),	 each	 study	 participant	
underwent	 a	medical	 examination	 after	 an	 overnight	 fast,	 during	which	 biological	 samples	 and	
physical	parameters	(including	height,	weight	and	blood	pressure	measurements)	were	obtained.	
The	 serum	 levels	 of	 TC,	 HDL-C	 and	 TG	 were	 directly	 determined	 by	 an	 automatic	 biochemical	
analyzer	 (Olympus	 AU2700,	 Japan),	 while	 the	 LDL-C	 concentration	 was	 estimated	 by	 using	 the	













The bacterial community structure of faecal samples	was	determined	by	16S	ribosomal	RNA	gene	
profiling	 with	 Illumina	 MiSeq	 System	 at	 the	 Center	 for	 life	 –	 Nanoscience,	 Istituto	 Italiano	 di	
Tecnologia	(Roma,	Italy).	Briefly,	metagenomic	DNA	was	extracted	from	200	±	10	mg	of	stool	within	
30	days	from	delivery	by	means	of	a	PowerFaecal	DNA	Isolation	Kit	 (Mo	Bio	Laboratories,	Cabru	
s.a.s.,	 Biassono,	 Italy)	 according	 to	 the	 manufacturer’s	 specifications.	 A	 DNA	 fragment	
encompassing	the	V3	and	V4	regions	of	the	16S	rRNA	gene	was	amplified	from	metagenomic	DNA	
with	the	primer	pair	selected	by	Klindworth	et	al.	(Klindworth	et	al.	2013).	The	sequencing	runs	were	
multiplexed	 and	 barcode	 sequences	 were	 used	 to	 discriminate	 the	 samples.	 16S	 rRNA	 gene	
sequence	 reads	 were	 analyzed	 through	 the	 bioinformatic	 pipeline	 Quantitative	 Insights	 Into	
Microbial	Ecology	(QIIME)	version	1.7.0	using	the	last	version	of	GreenGene	(gg_13_5)	as	reference	





SCFAs	 were	 quantified	 in	 the	 faecal	 samples	 collected	 from	 34	 subjects,	 including	 the	 15	 who	














ion	 injection	 time	 was	 100	 ms.	 The	MS	 data	 were	 processed	 using	 Xcalibur	 software	 (Thermo	
Scientific).	 Five-point	 external	 calibration	 curves	 prepared	 with	 analytical	 grade	 SCFAs	 (Sigma-
Aldrich,	Milan,	Italy)	were	adopted	to	quantify	acetate,	butyrate,	isobutyrate,	isovalerate,	lactate,	





All	 the	 statistical	 tests	 were	 performed	 considering	 three	 study	 populations:	 (i)	 hyperlipidemic	
subjects	 before	 HZN+S	 intake,	 (ii)	 hyperlipidemic	 subjects	 after	 HZN+S	 intake	 and	 (iii)	











as	 trends.	When	p-values	correction	was	applied,	 the	 false	discovery	 rate	 (FDR)	adjustment	was	
used.	
3.2.3	Results	











































To	 infer	 taxonomic	 signatures	 distinguishing	 the	 faecal	 microbiota	 structure	 of	 the	 15	
hyperlipidemic	participants	 and	 the	15	aged-matched	normolipidemic	 controls,	we	performed	a	
comparative	analysis	at	OTU	level	through	the	DESeq	negative	binomial	distribution	method.	We	










to	 the	phylum	Bacteroidetes	were	 significantly	enriched	 in	 controls	 compared	 to	hyperlipidemic	
samples,	whereas	only	3	Bacteroides	OTUs	were	reduced	(Figure	S1).	
	
Figure	3.	 Taxonomic	units	 in	 faecal	 samples	distinguishing	hyperlipidemic	 from	control	 subjects.	
Heat	map	based	on	the	normalized	abundance	of	OTUs	(horizontal	axis)	for	individual	faecal	sample	
(vertical	 axis).	 The	 figure	 includes	 only	 the	 OTUs	 that	 were	 significantly	 different	 between	




lactate	 in	 faecal	samples	by	UPLC-HR-MS	(Table	S1).	Specifically,	we	analyzed	the	data	 from	the	
faecal	samples	of	15	hyperlipidemic	subjects	undertaking	the	hazelnut	intervention	together	with	
19	additional	 faecal	 samples	 from	hyperlipidemic	subjects	at	baseline.	We	 found	that	 the	 faecal	
levels	of	several	SCFAs	were	significantly	different	between	hyperlipidemic	and	control	subjects;	
specifically,	 hyperlipidemia	 was	 associated	 with	 significantly	 lower	 concentrations	 of	 acetate,	












































































































































































**,	 p<0.01,	 ***,	 p<0.001	 according	 to	Mann-Whitney	U	 (unpaired)	 text.	 #,	 p<0.05	 according	 to	
Wilcoxon	(paired)	text.	
Overall,	 these	 data	 suggest	 that	 hyperlipidemia	 is	 potentially	 associated	 with	 gut	 microbiota	








Clostridiales.	 Specifically,	 13	 OTUs	 decreased	 after	 the	 dietary	 intervention,	 whereas	 17	 OTUs	
increased,	 including	 one	 OTU	 ascribed	 to	 Faecalibacterium	 prausnitzii	 and	 one	 belonging	 to	 an	
undefined	species	of	the	genus	Roseburia	(Figure	S3).	
Subsequently,	we	quantified	the	faecal	level	of	8	SCFAs	and	lactate	after	hazelnut	consumption	in	














lipoprotein	 cholesterol	 (HDL-C),	 non-HDL	 cholesterol,	 and	 triglycerides	 (TG).	 We	 found	 that	
lipidemic	parameters	changed	over	the	intervention	and	were	associated	to	variations	in	144	OTUs,	
19	of	which	were	significantly	different	between	dyslipidemic	and	control	samples	(Figure	5).	We	




of	Clostridiales,	 and	mostly	Lachnospiraceae,	 including	an	OTU	ascribed	 to	 the	genus	Roseburia.	




























































































217109 p_Firmicutes_c_Clostridia_o_Clostridiales_f_Christensenellaceae_g_s_ + +




































314095 ** p_Firmicutes_c_Clostridia_o_Clostridiales_f_Lachnospiraceae_g_Lachnospira_s_ ++



















left	 panel	 represents	 the	 mean	 of	 DESeq2-normalized	 abundances	 of	 the	 OTUs	 in	 control	 and	
hyperlipidemic	 (HL)	samples	before	 (T0)	and	after	 (T1)	 the	 intervention.	p	values	on	the	 left	are	
according	to	Wald	test	on	DESeq2-normalized	data	to	indicate	significantly	different	OTUs	between	
control	 and	 HL-T0	 samples;	 *,	 p<0.05;	 **,	 p<0.01;	 ***,	 p<0.001.	 The	 colors	 in	 the	 right	 panel	
represents	R-value	of	Spearman’s	correlation	of	the	differences	over	the	intervention	trial	between	













at	 around	3	 years	of	 age	 (Lozupone	et	al.	 2013;	Matamoros	et	al.	 2013;	Rodriguez	et	al.	 2015).	
Notably,	diet	can	play	a	leading	role	in	shaping	the	gut	microbiota	(Amato	et	al.	2015;	De	Filippo	et	
al.	 2010),	 therefore,	 possible	 differences	 in	 eating	 behavior	 between	 hyperlipidemic	 and	
normolipidemic	 counterparts	 could	 have	 been	 contributed	 to	 IME	 differences.	 However,	 we	
calculated	 through	 food	 diaries	 and	 food	 frequency	 questionnaires	 that	 the	 macronutrient	
contribution	 to	 the	 overall	 diet	was	 comparable	 between	 the	 two	 groups	 of	 subjects	 (data	 not	
shown).		
The	results	of	the	present	study	evidenced	that	the	faecal	microbiota	of	hyperlipidemic	subjects	is	
characterized	 by	 the	 alteration	 of	 numerous	 taxonomic	 units,	 many	 of	 which	 belong	 to	 the	
Clostridiales	order.	In	addition,	we	observed	in	hyperlipidemic	samples	a	reduced	representation	of	




bacteria	 from	 the	 phylum	 Firmicutes	 (mainly	 Clostridiales)	 and,	 particularly,	 a	 decrease	 of	
Bacteroidetes	(Armougom	et	al.	2009,	Baothman	et	al.	2016,	Ley	et	al.	2006,	Santacruz	et	al.	2010).	
In	addition,	the	enhanced	Firmicutes/Bacteroidetes	ratio	has	been	associated	with	a	high-protein,	
high-fat	Western	 diet	 (Amato	et	 al.	 2015)	 and	 distinguished	 European	 from	African	 1–6	 y	 aged	
children	(De	Filippo	et	al.	2010).	
Data	 on	 type	 2	 diabetes,	 which	 can	 be	 a	 hyperlipidemia-associated	 disease,	 indicated	 only	 a	
moderate	degree	of	gut	microbial	dysbiosis	and	rather	reported	a	‘functional	dysbiosis’,	in	which	a	





reported	 in	 intestinal	 inflammatory	 conditions	 (Sokol	 et	 al.	 2008,	 Van	 Immerseel	 et	 al.	 2010).	











2015).	 There	 is	 experimental	 evidence	 suggesting	 that	 acetate	 and	 propionate	 may	 regulate	
cholesterol	 metabolism	 by	 decreasing	 the	 activity	 of	 hepatic	 3-hydroxy-3-methylglutaryl-CoA	





subjects	 may	 contribute	 to	 their	 altered	 cholesterol	 metabolism.	 Interestingly,	 in	 our	 study,	
following	the	dietary	intervention	with	hazelnut,	we	observed	a	significant	increase	of	acetate	and	
a	 trend	 to	 rise	 of	 propionate	 levels,	 with	 assumed	 potential	 benefit	 for	 individuals	 with	
hyperlipidemia.	























(Burokas	et	al.	 2017),	whereas	pyruvate,	which	 can	derive	 from	bacterial	 autolysis	or	exfoliated	
apical	enterocytes,	has	been	associated	to	inflammatory	bowel	disease	(Huda-Faujan	et	al.	2010).	
However,	 the	 actual	 importance	of	 the	modification	of	 these	 organic	 acids	 in	 the	 human	 gut	 is	
unclear,	and	literature	is	too	limited	yet	to	allow	a	complete	interpretation	of	our	results.	
Although	the	hazelnut	intervention	modified	significantly	the	faecal	levels	of	SCFAs,	the	abundances	
of	 the	 bacterial	 taxa	 in	 the	 faecal	 microbiota	 were	 only	 limitedly	 affected.	 The	 observed	




(Deon	et	 al.	 2017a).	Moreover,	 despite	 the	 energy	 intake	 did	 not	 change	 following	 the	 regular	
consumption	of	hazelnuts,	it	should	be	underlined	that	an	increased	intake	of	total	fat	(about	+5%)	
and	monounsaturated	fatty	acids	was	observed	(Deon	et	al.	2017a).	Finally,	children	had	also	an	


















the	 link	 between	 inflammation	 and	 hyperlipidemia	 (Feingold	 and	Grunfeld	 2000,	 Tall	 and	 Yvan-
Charvet	 2015).	 Reportedly,	 Faecalibacterium	 prausnitzii	 is	 associated	 with	 inflammatory	 bowel	
diseases	 and	 its	 supplementation	 abolished	 inflammation	 (Sokol	 et	 al.	 2008).	 Furthermore,	 the	
abundance	of	Akkermansia	muciniphila	is	lower	in	obesity	and	diabetes	and	the	administration	of	
this	 bacterium	 has	 been	 shown	 to	 reduce	 obesity,	 fat	 mass	 inflammation	 and	 also	 plasma	
cholesterol	and	triglycerides	(Everard	et	al.	2013,	Plovier	et	al.	2017).	This	 last	example	is	also	in	
accordance	 with	 the	 present	 study,	 where	 the	 changes	 of	 some	 plasma	 lipids	 are	 inversely	
associated	with	this	intestinal	commensal.	In	addition,	the	change	of	Bacteroides	fragilis,	which	is	
another	species	with	a	reported	potential	anti-inflammatory	role	in	the	gut	(Troy	and	Kasper	2010),	
























OTU nr. Taxonomy C HL
198774 p_Actinobacteria;c_Coriobacteriia;o_Coriobacteriales;f_Coriobacteriaceae;g_Adlercreutzia;s_ 1.48 2.6E-03 1.75E-02
3013444 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_;g_;s_ -2.42 5.4E-09 2.20E-07
183395 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Barnesiellaceae];g_;s_ -2.29 3.3E-03 2.03E-02
3500642 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Barnesiellaceae];g_;s_ -1.64 6.8E-03 3.58E-02
194395 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Barnesiellaceae];g_;s_ -1.54 1.0E-03 8.29E-03
208479 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Odoribacteraceae];g_Butyricimonas;s_ -2.02 1.3E-03 1.04E-02
177353 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Odoribacteraceae];g_Odoribacter;s_ -2.73 2.7E-09 1.36E-07
196947 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_[Paraprevotellaceae];g_[Prevotella];s_ -3.17 1.0E-14 2.80E-12
228601 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -2.84 2.6E-11 2.19E-09
4467447 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -1.86 1.9E-04 2.12E-03
326662 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -1.85 8.0E-06 1.55E-04
157748 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -1.57 1.4E-03 1.08E-02
1126638 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ -1.14 6.2E-03 3.34E-02
195508 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_caccae -2.23 2.4E-03 1.62E-02
184567 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_caccae -2.23 1.0E-04 1.42E-03
320120 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_caccae -2.18 4.1E-03 2.37E-02
344525 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_eggerthii -2.87 9.1E-07 2.28E-05
4387250 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ovatus -1.50 2.2E-03 1.57E-02
585914 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Porphyromonadaceae;g_Parabacteroides;s_distasonis -2.88 1.8E-07 5.22E-06
4374084 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Porphyromonadaceae;g_Parabacteroides;s_distasonis -1.46 3.6E-04 3.51E-03
336214 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Rikenellaceae;g_;s_ -3.26 9.0E-15 2.80E-12
439437 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_S24-7;g_;s_ -2.72 2.9E-10 2.11E-08
208409 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_S24-7;g_;s_ -2.55 2.0E-09 1.13E-07
339905 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_S24-7;g_;s_ -2.02 1.1E-06 2.63E-05
188735 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ 1.35 3.1E-03 1.93E-02
583656 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ 2.47 1.4E-04 1.68E-03
356827 p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides;s_ 2.77 9.0E-08 2.90E-06
1787644 p_Cyanobacteria;c_Chloroplast;o_Streptophyta;f_;g_;s_ -2.63 1.1E-09 6.79E-08
1136443 p_Deferribacteres;c_Deferribacteres;o_Deferribacterales;f_Deferribacteraceae;g_Mucispirillum;s_schaedleri -5.66 6.8E-42 7.47E-39
4431922 p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Streptococcaceae;g_Streptococcus;s_ -1.24 8.9E-04 7.57E-03
260890 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -3.50 6.6E-17 3.66E-14
848615 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -3.35 2.8E-07 7.79E-06
275139 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -3.18 8.2E-14 1.82E-11
345862 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.86 4.3E-12 5.97E-10
198200 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.80 6.5E-11 5.13E-09
277265 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.60 4.3E-10 2.94E-08
330460 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.48 2.8E-09 1.36E-07
272072 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.45 1.3E-08 4.96E-07
361727 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.45 1.9E-05 3.25E-04
356627 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -2.26 8.6E-08 2.90E-06
188861 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.92 3.4E-03 2.04E-02
180307 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.87 4.0E-05 6.15E-04
198119 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.86 3.3E-06 7.17E-05
192741 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.76 3.8E-03 2.24E-02
1040889 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.74 3.6E-03 2.17E-02
187081 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.73 3.0E-03 1.91E-02
201772 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.68 1.3E-05 2.27E-04
976470 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.64 5.9E-03 3.22E-02
4358921 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.62 1.1E-04 1.42E-03
185034 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.56 3.7E-03 2.18E-02
194095 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.55 7.4E-06 1.46E-04
389371 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.53 5.0E-03 2.81E-02
364736 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.51 8.1E-03 4.11E-02
195799 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.51 4.8E-04 4.40E-03
188832 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.43 2.4E-04 2.51E-03
188596 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.25 4.9E-03 2.77E-02
357389 p_Firmicutes;c_Clostridia;o_Clostridiales;f_;g_;s_ -1.21 4.5E-04 4.18E-03
322560 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Clostridiaceae;g_SMB53;s_ -1.19 8.2E-03 4.11E-02
524404 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.98 4.0E-09 1.69E-07
536910 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.77 1.1E-05 2.07E-04
561171 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.52 2.7E-04 2.77E-03
846141 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.50 1.8E-05 3.17E-04
185486 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.45 2.2E-06 4.91E-05
336830 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.38 8.2E-04 7.07E-03
177061 p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_;s_ -2.27 6.0E-05 8.83E-04
Media log2 Fold 
Change pvalue padj
Figure S1. OTUs distinguishing control and hyperlipidemic subjects determined by using the DESeq2 negative binomial distribution
method on 16S rRNA gene profiling data of a single fecal sample per subject. The colors in the heatmap represents the mean of
normalized abundances of the reported OTUs. The taxonomic lineage of each taxon is shown; p, phylum; c, class; o, order; f, family; g,
genus; s, species. Positive fold changes (shown on a red background) indicate OTU overrepresentation in normolipidemic controls
compared to hyperlipidemic samples; negative fold changes (shown on a green background) indicate a decrease of OTU abundance in





























Fig. S2. Fecal levels of short chain fatty acids in hyperlipidemic and control subjects. Black	
circles	refer	to	control	samples	analyzed	in	the	present	study;	white	circles	refer	to	data	obtained	



















Fig. S2. Fecal levels of short chain fatty acids in hyperlipidemic and control subjects. Black circles refer 
to control samples analyzed in the present study; white circles refer to data obtained from healthy adults in a 
previous study (Gargari et al., 2016, doi: 10.1128/AEM.01753-16); grey triangles r fer to samples from 
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In	particular,	 IBS	 is	conventionally	classified	 in	four	subtypes	according	to	bowel	habits:	 IBS	with	
constipation	(IBS-C),	IBS	with	diarrhoea	(IBS-D),	IBS	alternating	constipation	and	diarrhoea	(mixed	
IBS,	IBS-M),	and	unsubtyped	IBS	(IBS-U)	(Mearin	et	al.	2016).	
Elucidations	of	 the	diverse	mechanisms	underlying	 the	pathophysiology	of	 IBS	 subtypes	 are	 still	
lacunose;	furthermore,	conclusively	validated	biomarkers	are	not	available	(Kim	et	al.	2017).	In	a	
recent	paper,	Collins	S.	M.	proposed	to	explain	the	intestinal	dysfunctions	associated	to	IBS	through	
a	gut-microbiota-centered	model	 (Collins	2014).	According	to	this	model,	 triggers	 like	antibiotics	
use,	 infections	 and/or	 stress	 affect	 host	 functions	 such	 as	 mucin	 production,	 gut	 motility	 and	
hormone	 secretion,	 leading	 to	 dysbiosis	 (i.e.,	 compositional	 and	 functional	 alterations	 of	 the	
intestinal	 microbial	 ecosystem;	 IME),	 which	 in	 turn	 promotes	 chronic	 gut	 dysfunctions.	 Hence,	
Collins’	model	 highlights	 the	 central	 role	 of	 the	 intestinal	microbiota	 in	 IBS,	 in	 agreement	with	
clinical	evidences	of	the	benefits	generated	by	gut	microbiota-targeting	strategies	such	as	the	use	
of	antibiotics	(e.g.	rifaximin)	(Li	et	al.	2016)	and	probiotics	(Guglielmetti	et	al.	2011,	O'Mahony	et	al.	




or	 the	 expansion	 of	 Proteobacteria	 and	 Veillonella	 spp.	 (Shukla	 et	 al.	 2015,	 Taverniti	 and	




reduction	 of	 Bifidobacteria,	 lactobacilli,	 and	 the	 genus	 Desulfovibrio	 was	 observed	 in	 IBS-D	
compared	to	IBS-C	(Malinen	et	al.	2005);	the	same	study	also	showed	the	increase	of	Veillonella	in	
IBS-C	(Malinen	et	al.	2005).	The	IBS-C	subtype	was	also	associated	to	the	expansion	of	ruminococci	
(Kassinen	 et	 al.	 2007,	 Lyra	 et	 al.	 2009).	Moreover,	 higher	 aerobic	 counts	 in	 faecal	 samples	was	
observed	 in	 IBS-D	 by	means	 of	 a	 culture-based	 analyses	 (Carroll	 et	 al.	 2010).	 In	 addition,	more	




Besides	 the	 taxonomic	 identity	of	 the	bacteria	 constituting	 the	 IME,	a	predominant	 role	 for	 the	
intestinal	microbiota-host	interaction	is	played	by	bacterial	metabolites	in	the	gut	and,	among	them,	
particularly	 by	 the	 short	 chain	 fatty	 acids	 (SCFAs)	 (Koh	 et	 al.	 2016),	which	 are	 produced	 in	 the	
intestinal	lumen	by	bacterial	fermentation	in	copious	quantity	(exceeding	hundreds	of	mmol	per	kg	
of	feces	[Gargari	et	al.	2016]).	Reportedly,	acetate,	butyrate	and	propionate,	which	are	the	three	





Inspired	 by	 the	 above	 considerations,	 in	 this	 study,	 we	 aimed	 to	 characterized	 the	 IME	 in	 IBS	
subtypes	by	means	of	16S	ribosomal	RNA	(rRNA)	gene	profiling	and	SCFAs	quantification	in	faecal	
samples	collected	during	a	multicentre	intervention	trial	that	we	recently	performed	to	assess	the	
effect	 of	 a	 probiotic	 preparation	 on	 the	 IBS	 symptoms	 of	 40	 patients	 (Cremon	 et	 al.,	 2017).	 In	
addition,	the	clinical	and	immunological	data	collected	during	the	trial	were	used	to	investigate	the	
potential	correlations	existing	in	IBS	subtypes	between	the	IME	and	host	physiological	and	clinical	








Italian	 hospitals	 as	 previously	 described	 (Cremon	 et	 al.,	 2017).	 In	 brief,	 the	 inclusion	 criteria	
comprised	 a	 positive	 diagnosis	 of	 all	 IBS	 subtypes,	 age	 between	 18	 and	 65	 years,	 negative	
colonoscopy	 or	 barium	 enema	 examination	 within	 the	 previous	 2	 years,	 and	 negative	 relevant	
additional	 screening	or	consultation	whenever	appropriate.	Patients	were	excluded	 if	 they	were	
pregnant,	breast-feeding,	or	not	using	reliable	methods	of	contraception.	The	exclusion	criteria	also	
included	 intestinal	 organic	diseases,	 such	as	 celiac	disease	 ascertained	by	 the	detection	of	 anti-
transglutaminase	 antibodies,	 diverticular	 disease,	 or	 inflammatory	 bowel	 diseases	 (IBDs;	 e.g.,	
Crohn's	disease,	ulcerative	colitis,	infectious	colitis,	ischemic	colitis,	or	microscopic	colitis);	previous	
major	 abdominal	 surgery;	 untreated	 food	 intolerance,	 such	 as	 ascertained	 or	 suspected	 lactose	
intolerance	as	defined	by	anamnestic	evaluation	or,	if	appropriate,	lactose	breath	test;	consumption	


























Microbial	 Ecology	 (QIIME)	 version	 1.7.0	 (Caporaso	 et	 al.	 2010)	 with	 the	 GreenGenes	 database	
























were	 analyzed	 using	 R	 statistic	 software	 (version	 3.1.2)	 and	 QIIME.	 Statistically	 significant	
differences	 were	 determined	 through	 the	 Wilcoxon-Mann-Whitney	 test	 for	 unpaired	 data.	
Statistically	significant	differences	at	OTU	level	between	IBS	subtypes	were	determined	by	using	the	




significance	 in	 the	 range	0.05<P<0.10	was	accepted	as	 trend.	UNIFRAC	algorithms	were	used	 to	











five	 samples	analyzed	 for	each	 subject	was	mostly	higher	 than	 the	differences	occurring	among	
different	 subjects	 (Supplementary	 figure	 S1).	 For	 this	 reason,	 besides	 considering	 the	data	of	 a	
single	 16S	 rRNA	 gene	 profiling	 determination	 per	 subject	 (single	 profiling	 data;	 n=40),	 we	 also	
performed	the	analyses	with	data	corresponding	to	the	medians	of	 five	16S	rRNA	gene	profiling	









Figure	 1.	 Ecological	 β-diversity	 of	 the	 faecal	 microbiota	 in	 IBS	 subtypes.	 Principal	 coordinates	









the	 bacterial	 genera	 (Gargari	 et	 al	 2016).	 An	 optimal	 number	 of	 three	 groups	 of	 samples	 was	
generated,	nonetheless	the	Silhouette	coefficient,	which	validate	the	consistency	within	groups	of	




taxonomic	 overview	 of	 all	 198	 IBS	 faecal	 sample	 analyzed	 revealed	 that	 the	 first	 seven	 most	
abundant	genera	belong	to	the	Firmicutes	Gram	positive	order	Clostridiales	(Supplementary	Figure	
S4B);	in	particular,	collectively,	whereas	the	Clostridiales	accounted	for	about	the	75	%	of	detected	
bacteria,	 the	 relative	 abundance	 of	 members	 of	 the	 order	 Bacteroidales	 was	 lower	 than	 10	 %	
(Supplementary	Figure	S4B).	On	the	contrary,	in	our	previous	studies,	we	found	that	Bacteroidales,	
and	 particularly	 the	 genera	 Bacteroides	 and	 Prevotella,	 were	 dominant	 genera	 of	 the	 faecal	
microbiota	of	the	healthy	volunteers	(Ferrario	et	al	2014,	Gargari	et	al	2016).	Therefore,	in	order	to	
assess	 if	 the	 observed	 expansion	 of	 Clostridiales	 compared	 to	 Bacteroidales	 is	 an	 actual	
microbiological	 feature	 of	 the	 investigated	 IBS	 patients,	 we	 analyzed	 additional	 faecal	 samples	
collected	from	16	healthy	adults	through	16S	rRNA	gene	profiling	adopting	the	same	protocol	used	
for	IBS	samples.	The	obtained	results	indicated	that	Clostridiales	are	largely	dominant	also	in	the	
feces	 of	 control	 subjects	 (Figure	 S4C),	 demonstrating	 that	 the	 alteration	 of	 the	
Clostridiales/Bacteroidales	 ratio	 observed	 in	 IBS	 samples	 depended	 on	 technical	 issues	 and,	






do	 not	 vary	 significantly	 among	 IBS	 subtypes.	 The	 results	 of	 this	 study	 evidenced	 a	 general	






was	 performed	 both	 on	 single	 and	 median	 profiling	 data,	 excluding	 IBS-M	 subtype	 because	












(Figure	 2B	 and	 Supplementary	 Figure	 5).	 Largely	 most	 of	 the	 discriminating	 OTUs	 were	
taxonomically	 ascribed	 to	 the	 order	 Clostridiales	 (Figure	 2B	 and	 Supplementary	 Figure	 5);	
particularly,	 IBS-C	 were	 distinguished	 from	 IBS-D	 by	 numerous	 Clostridiales-associated	 OTUs	
belonging	 to	 the	 families	 Ruminococcaceae	 (in	 particular,	 the	 genus	 Ruminococcus)	 and	
Lachnospiraceae.	In	addition,	two	OTUs	ascribed	to	Bifidobacterium	adolescentis	were	increased	in	
IBS-C	 whereas	 OTUs	 associated	 to	 the	 order	 Bacteroidales	 and	 to	 the	 Firmicutes	 species	
Eubacterium	biforme	were	enriched	in	IBS-D	samples	(Figure	2B	and	Supplementary	Figure	5).	
Overall,	these	results	indicate	that	the	faecal	microbiotas	of	IBS-C	and	IBS-D	are	characterized	by	a	




























normalized	 relative	 abundances	 of	 the	 reported	 OTUs.	 The	 taxonomic	 lineage	 of	 each	 taxon	 is	
shown;	p,	phylum;	c,	class;	o,	order;	f,	family;	g,	genus;	s,	species.	Positive	fold	changes	(shown	on	
a	red	background)	designate	OTU	overrepresentation	in	the	IBS	subtype	indicated	in	the	column	on	
the	 left	 of	 the	 Normalized	 Base	Mean;	 negative	 fold	 changes	 (shown	 on	 a	 green	 background)	
designate	the	OTU	overrepresentation	in	the	IBS	subtype	indicated	in	the	column	on	the	right	of	the	
Normalized	 Base	 Mean.	 The	 heatmap	 in	 the	 right	 panel	 represents	 R-value	 of	 Spearman’s	









valerate,	 isovalerate	 and	 propionate	 were	 quantified	 in	 the	 IBS	 faecal	 samples	 and	 used	 to	
characterize	the	IBS	subtypes.	As	for	the	faecal	microbiota	composition,	the	analyses	of	the	SCFAs	
were	 carried	out	 considering	 the	 levels	determined	 in	 a	 single	 faecal	 sample	per	patient	 (single	
analysis	SCFA	levels,	n=37;	Supplementary	Figure	6)	and	the	median	values	of	five	measurements	
per	patient	(median	SCFA	levels,	n=37;	Figure	3A).	The	organic	acids	were	also	quantified	in	the	IBS-






significantly	 lower	 in	 IBS-C,	whereas	 the	 faecal	 level	of	valerate	was	 significantly	higher	 in	 IBS-D	




































enriched	 in	 IBS-C	 samples	 were	 negatively	 correlated	 with	 the	main	 faecal	 SCFAs	 (i.e.	 acetate,	
propionate	 and	 butyrate),	whereas	many	Clostridiales	 OTUs	 overrepresented	 in	 IBS-D	 positively	
correlated	with	 the	 same	 SCFAs,	 particularly	 acetate	 (Figure	 2B).	Moreover,	most	 of	 the	 IBS-C-
enriched	OTUs	 that	were	 inversely	 linked	 to	SCFAs,	at	 the	 same	 time,	 correlated	positively	with	
several	cytokines	and	negatively	with	 IgA	and	 IFNγ.	Conversely,	great	part	of	 the	 IBS-D-enriched	
OTUs	that	were	positively	associated	to	SCFAs,	were	also	positively	correlated	with	the	faecal	type	
determined	 through	 the	 Bristol	 stool	 scale	 (Figure	 2B).	 Accordingly,	 we	 also	 found	 a	 positive	









































the	 identification	 of	 microbial	 markers	 distinguishing	 this	 dysfunction	 from	 healthy	 condition	
(Zhuang	et	al.	 2017);	however,	much	 less	attention	has	been	 spent	 to	 compare	 the	 IMEs	of	 IBS	
subtypes.	 In	 this	 context,	 recently,	 Tap	 and	 collaborators	 reported	 that	 neither	 richness	 nor	
variability	of	the	intestinal	microbiota	differed	among	IBS	groups	(Tap	et	al.	2017).	Accordingly,	we	
did	not	find	significant	differences	in	both	α-	and	β-diversity	among	the	different	IBS	subtype.	In	a	
previous	 study,	 Jeffery	et	al.	 (Jeffery	et	al.	 2012)	used	pyrosequencing	of	 the	16S	 rRNA	gene	 to	
determine	 the	microbiota	 composition	 in	a	 faecal	 specimen	 from	37	 IBS	patients.	Notably,	 they	
identified	distinct	 IBS	patients’	subsets,	which	however	did	not	correspond	to	the	traditional	 IBS	
subtypes	 (Jeffery	et	al.	 2012).	On	 the	contrary,	 in	 the	present	 study,	we	 found	 that	 the	 relative	
abundance	of	numerous	OTUs	were	significantly	different	among	IBS	subtypes.	Particularly,	here	
we	 report	 that	 major	 differences	 exist	 in	 Clostridiales	 OTUs	 between	 IBS-C	 and	 IBS-D	 feces;	
conversely,	IBS-U	faecal	samples	differed	much	less	from	IBS-C	and	IBS-D	in	terms	of	OTUs.	
In	 light	of	 the	rapidly	expanding	 literature	demonstrating	the	clinical	efficacy	of	dietary	patterns	
based	 on	 drastically	 reduced	 "Fermentable,	 Oligo-,	 Di-,	 Mono-saccharides	 and	 Polyols"	 (low-
FODMAP	diet)	(Eswaran	et	al.	2016),	we	can	speculate	that	Clostridiales	bacteria	in	the	gut	of	IBS	
patients	 may	 represent	 a	 therapeutic	 target.	 FODMAPs,	 in	 fact,	 are	 preferential	 fermentation	





2014,	 Halmos	 et	 al.	 2015,	McIntosh	 et	 al.	 2016).	 Therefore,	 low-FODMAP	 diet	 can	 be	 properly	
considered	a	Clostridiales-modulating	intervention.	
Many	OTUs	 that	 discriminated	 IBS-C	 from	 IBS-D	 samples	 belonged	 to	 the	Clostridiales’	 families	
Ruminococcaceae	 and	 Lachnospiraceae.	 The	 importance	 of	 these	 gut	 bacteria	 in	 IBS	 was	 also	
evidenced	 by	 the	 study	 of	 Tap	 et	 al.,	 who	 defined	 a	 composite	 gut	microbial	 signature	 for	 IBS	
severity	 constituted	 by	 90	 OTUs,	 among	 which,	 at	 the	 family	 level,	 principally	 OTUs	 within	
Lachnospiraceae	 and	 Ruminococcaceae	 were	 found	 (Tap	 et	 al.	 2017).	 Lachnospiraceae	 and	
Ruminococcaceae	 are	 the	most	 commonly	 retrieved	 families	 in	 the	 active	 intestinal	microbiota	
(Peris-Bondia	et	al.	2011)	and	are	considered	the	principal	degraders	of	plant	carbohydrates	in	the	
human	colon	 (Flint	et	al.	 2012).	 For	 instance,	 inside	 the	Ruminococcaceae	 family,	Ruminococcus	
champanellensis	 is	 the	only	known	human	 intestinal	bacterium	that	can	degrade	microcrystaline	
cellulose	 (Chassard	 et	 al.	 2007),	 whereas	 certain	 strains	 of	 Faecalibacterium	 prausnitzii	 were	
reported	to	catabolize	apple	pectin;	furthermore,	bacteria	phylogenetically	related	to	Ruminococcus	
albus	were	demonstrated	to	utilize	galactomannan	(Salyers	et	al.	1977).	Pectin	can	also	be	degraded	








acetogenesis	 (Bernalier	 et	 al.	 1996,	 Rey	 et	 al.	 2010),	 and	 butyrate	 or	 propionate	 from	 lactate	
utilization	(Duncan	et	al.	2004,	Rios-Covian	et	al.	2016).	
Considering	the	above-mentioned	 literature,	 the	observed	differential	OTU	distribution	between	
IBS-C	 and	 IBS-D	 let	 presume	 that	 the	 IBS	 subtypes	 may	 have	 dissimilar	 faecal	 levels	 of	 SCFAs.	
Accordingly,	we	found	significantly	lower	levels	of	acetate,	butyrate,	propionate	and	valerate	in	IBS-
C	samples.	Notably,	in	our	study,	such	differences	were	found	to	be	significant	also	considering	the	





Scientific	 literature	 on	 intestinal	 SCFAs	 in	 IBS	 is	 quite	 limited	 and	 contradictory,	 showing	 no	
alteration,	 augmented,	 or	 decreased	 levels	 compared	 to	 healthy	 controls	 (Halmos	 et	 al.	 2014,	
Mortensen	 et	 al.	 1987,	 Rajilic-Stojanovic	 et	 al.	 2015,	 Tana	 et	 al.	 2010,	 Treem	 et	 al.	 1996).	
Nevertheless,	our	data	are	in	accordance	with	the	study	of	Ringel-Kulka	et	al.	(Ringel-Kulka	et	al.	






Kulka	 et	 al.	 2015):	 (1)	 compared	 to	 IBS-C,	 IBS-D	patients	 are	 characterized	 by	 increased	 colonic	
fermentation	 that	 leads	 to	 higher	 faecal	 levels	 of	 SCFAs,	which	 stimulate	 the	 intestinal	motility	
(Fukumoto	et	al.	2003)	and,	then,	reduce	transit	time;	or	(2)	decreased	transit	time	in	IBS-D	patients	
slows	down	SCFAs	absorption,	determining	higher	SCFAs	concentration	in	the	feces	compared	to	





other	hand,	 it	 can	be	even	 speculated	 that	bacteria	 in	 the	 colon	may	be	differently	 affected	by	
modified	 intestinal	 transit	 (for	 instance	due	to	variable	adhesion	ability	and/or	cell	 reproduction	
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of	 interaction”.	 Before	 the	 introduction	 of	 the	 concept	 of	 the	 holobiont,	 scientific	 research	




each	 kind	 of	 dietary	 intervention	 or	 pharmaceutical	 treatment	 does	 also	 have	 an	 impact	 on	





4.1	 Conclusion	 of	 the	 probiotic	 B.	 bifidum	 Bb	
crossover	intervention	trial	
The	 intervention	 trial	 based	 on	 the	 administration	 of	 B.	 bifidum	 strain	 Bb	 has	 shown	 that	 the	
probiotic	 treatment	 modified	 the	 relative	 abundances	 of	 bacterial	 taxa	 that	 have	 often	 been	










health	 claim	 assessment	 by	 the	 EFSA.	 In	 particular,	 our	 study	 demonstrates	 that	 a	 single	 daily	
administration	of	one	bacterial	strain	approximately	at	the	minimal	recommended	dose	(1	billion	
CFU	[Ministero	della	salute	2013])	can	modify	the	human	 intestinal	microbial	ecology	of	healthy	
(not	diseased)	adults	 in	a	significant	 fashion.	These	 findings	emphasize	the	need	to	reassess	 the	
notion	that	probiotics	do	not	influence	the	complex	and	stable	intestinal	microbial	ecosystem	of	a	





















4.3	 Conclusion	 of	 the	 IBS-subtypes	 observational	
study	
This	 descriptive	 study	 demonstrates	 that	 the	 altered	 distribution	 of	 bacteria	 within	 the	 Gram-
positive	 order	 Clostridiales	 distinguishes	 the	 intestinal	 microbial	 ecosystem	 of	 IBS	 subtypes,	
plausibly	 contributing	 to	 the	 observed	 altered	 faecal	 levels	 of	 the	 SCFAs	 acetate,	 butyrate	 and	
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tutor.	 Questa	 sua	 maturità	 caratteriale	 è	 stata	 essenziale	 per	 poter	 passare	 questi	 3	 anni	 di	









la	 loro	esperienza	di	 tesi,	 con	cui	ho	 instaurato	un	rapporto	di	amicizia	 fin	da	subito.	Ci	 tengo	a	
nominare	 Carlo	 con	 cui	 ho	 lavorato	 pochissimo	 ma	 mi	 è	 stato	 da	 subito	 simpaticissimo	 e	 che	
probabilmente	 è	 il	 primo	 ad	 aver	 citato	 il	 mio	 articolo	 in	 un	 lavoro	 scientifico.		
Non	posso	non	inserire	qui	il	mio	tutor/tirocinante	Mugetti	che	mi	ha	insegnato	i	primi	passi	nell’uso	




















ad	 accarezzare	 mammiferi	 marini	 (per	 quanto	 potrebbe	 essere	 divertente	 e	 rilassante).		
	
	
	
	
		
	
	
